831
+0.73%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AFC-HD AMS Life Science Co
Its shares trade on Tokyo Stock Exchange under the ticker 2927.T. It has been listed since 3 March 2005. In the fiscal year to 31 August 2026, it reported revenue of ¥34.32bn and net income of ¥1.20bn. At that date it held total assets of ¥49.05bn and shareholders' equity of ¥16.21bn.
AFC-HD AMS Life Science Co., Ltd. is a general OEM (Original Equipment Manufacturing) manufacturer that delivers quality products to meet the entire spectrum of customer needs. The company is headquartered in Shizuoka-Shi, Shizuoka-Ken. The company went IPO on 2005-03-03. The firm is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The firm operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The firm is also engaged in the management of restaurants through subsidiary.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 3 Mar 2005
- Employees
- 878
- Website
- ams-life.com ↗
Leadership
Pay as last reported
- Mr. Takehiko AsayamaChairman of the Board, Representative Director, since 2003
- Mr. Yasuhiro MatsunagaPresident, Representative Director, since 2020
- Mr. Shunji SasaharaPresident of Subsidiaries, Director, since 2020
- Mr. Shigenori FukuchiSenior Managing Director, since 2005
- Mr. Shigeho MinamikataManager of Chairman's Office, President of Subsidiary, Director, since 2021
- Mr. Nobue HamabeDirector of Accounting , Director, since 2022
- Mr. Enoyuki MaekawaDirector of General Affairs, Director, since 2022
- Mr. Kazunori TakadaChief Director of Administration, Director, since 2021
- Mr. Naoya UnnoChief Director of Technology Development, Director, since 2003
- Mr. Yosuke AikawaIndependent Director
- Mr. Masaki TakahashiIndependent Director
- Mr. Hiroshi UminoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AFC-HD AMS Life Science Co Ltd employs 878 full-time employees in Shizuoka-shi.
- The company operates in two business segments: Healthcare and Pharmaceutical.
- AFC-HD AMS Life Science Co Ltd offers OEM services for health foods and cosmetics.
Weaknesses
- The company's IPO date was 3 March 2005, which is over 19 years ago.
- AFC-HD AMS Life Science Co Ltd has no mention of international expansion in its business description.
- The firm's headquarters city is Shizuoka-shi, which may limit market reach.
Opportunities
- The Healthcare segment can expand into natural foods sales in Japan.
- The Pharmaceutical segment can grow through generic drug sales in Japan.
- AFC-HD AMS Life Science Co Ltd can leverage its OEM capabilities for new markets.
Threats
- The company faces competition from other Japanese health food manufacturers.
- The Pharmaceutical segment may face regulatory challenges in Japan.
- AFC-HD AMS Life Science Co Ltd's reliance on the Japanese market poses risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.